• Publications
  • Influence
Weekly paclitaxel plus trastuzumab in metastatic breast cancer pretreated with anthracyclines-a phase II multipractice study
BackgroundThe 3-weekly combination of trastuzumab and paclitaxel has been approved for the treatment of advanced breast cancer based on a large pivotal study. However, mono and combinationExpand
  • 18
  • 2
Biweekly schedule of pegylated liposomal doxorubicin (PLD) induces low rates of skin toxicities: Results of a phase-II trial in heavily preteated patients with relapsed ovarian cancer
5072 Background: Pegylated liposomal doxorubicin ( PLD) formulation has been approved for the treatment of recurrent ovarian cancer (ROC). Toxic skin reactions were reported as being the dose-limit...
  • 5
The SUCCESS-C trial: Interim analysis of toxicity evaluating the role of an anthracycline-free chemotherapy regimen in the adjuvant treatment of HER2/neu-negative breast cancer.
1070 Background: Taxane-based anthracycline containing chemotherapy has been established as treatment option in the adjuvant setting of early breast cancer. Indication was recently enlarged for highExpand
  • 1
Sequential therapy with carboplatin (C) followed by paclitaxel (P) as first-line chemotherapy in 105 patients with advanced ovarian cancer (AOC): Results of a multicenter phase II study of the
5533 Background: For the adjuvant setting of AOC after primary radical surgery the combination of paclitaxel and platinum in a three weeks schedule has emerged as the current standard. Exposition d...
Gynecologic oncology
OBJECTIVES: Caelyx is a novel pegylated liposomal doxorubicin formulation and has been approved for the treatment of recurrent ovarian cancer. METHODS: We performed a multi-institutional phase-IIExpand